Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results


      News provided by

      POMDOCTOR LIMITED

      Dec 03, 2025, 16:15 ET

      Share this article

      Share this article


      GUANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its unaudited financial results for the six months ended June 30, 2025.

      Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "The first half of fiscal year 2025 reflected our deliberate and disciplined efforts to balance business expansion with operational rigor. Despite a challenging macroeconomic environment and intensified market competition, we strived to strengthen our market coverage and penetration, while optimizing and diversifying our revenue streams through the vigorous promotion of our internet-hospital services and online sales. During the period, we continued to solidify our partner-doctor pool by offering higher service fees, and at the same time meaningfully enhanced our collaboration with pharmaceutical manufacturers to drive online sales and adapt to China's evolving healthcare landscape. These initiatives resulted in a 16.2% increase in net revenue, highlighted by growth of 83.2% in our online-pharmacy businesses.

      At the same time, we maintained strict cost controls and operational discipline, sustaining a stable gross profit margin of 16.2%. Gross profit increased 16.3% year over year, despite higher sales and marketing expenses, a larger contribution from lower-margin pharmacy products, and continued investments in customer acquisition. We prioritized retaining doctor resources while prudently reducing advertising spending, reinforcing the foundation for sustainable growth under a stable pharmaceutical supply chain.

      Notably, our successful initial public offering (IPO) in October provided us with additional capital resources and expanded opportunities for future growth, further enriching our strategic options and strengthening our execution capabilities. Looking ahead, we are confident in our ability to continue improving operational performance and creating long-term value for our shareholders."

      First Half of Fiscal 2025 Financial Summary

      • Net revenues for the six months ended June 30, 2025 were RMB174.5 million (US$24.4 million), representing a 16.2% increase from RMB150.2 million in the six months ended June 30, 2024.
      • Gross profit increased by 16.3% from RMB24.3 million in the six months ended June 30, 2024, to RMB28.3 million (US$4.0 million) in the six months ended June 30, 2025.
      • Gross profit margin remained stable at 16.2% in the six months ended June 30, 2024 and 2025.
      • Net loss was RMB19.9 million (US$2.8 million) for the six months ended June 30, 2025, compared with RMB14.0 million for the six months ended June 30, 2024.
      • Net loss per share, basic and diluted, was RMB11.45 (US$1.60) for the six months ended June 30, 2025, compared with RMB10.58 for the six months ended June 30, 2024.

      Unaudited Financial Results for the First Half of Fiscal 2025

      • Net revenues for the six months ended June 30, 2025 were RMB174.5 million (US$24.4 million), representing a 16.2% increase from RMB150.2 million in the six months ended June 30, 2024, which was primarily attributable to the increase in the net revenues from Internet hospital. Net revenues from Internet hospital increased by 82.4% from RMB36.8 million in the six months ended June 30, 2024 to RMB67.2 million (US$9.4 million) in the six months ended June 30, 2025, primarily attributable to the increase in revenues generated from online pharmacy sales. In the first half of 2025, the Company strengthened its cooperation with pharmaceutical manufacturers to sell their products through its Internet hospital platform. As a result, revenue from the Company's online pharmacy sales increased from RMB36.3 million in the six months ended June 30, 2024 to RMB66.4 million (US$9.3 million) in the six months ended June 30, 2025.
      • Cost of revenues increased by 16.2% from RMB125.8 million in the six months ended June 30, 2024 to RMB146.2 million (US$20.4 million) in the six months ended June 30, 2025, primarily due to the increase in cost of revenues in online pharmacy sales from RMB20.4 million in the six months ended June 30, 2024 to RMB40.0 million (US$5.6 million) in the six months ended June 30, 2025, which was in line with the increase in the Company's net revenues from Internet hospital.
      • Gross profit increased by 16.3% from RMB24.3 million for the six months ended June 30, 2024, to RMB28.3 million (US$4.0 million) in the six months ended June 30, 2025.
      • Gross profit margin remained stable at 16.2% in the six months ended June 30, 2024 and 2025. The gross profit margin of the Company's Internet hospital decreased from 44.7% in the six months ended June 30, 2024 to 40.5% in the six months ended June 30, 2025, mainly due to the increase in the online pharmacy sales of products with lower gross profit margin. The gross profit margin of the Company's pharmaceutical supply chain business decreased from 6.9% in the six months ended June 30, 2024 to 1.1% in the six months ended June 30, 2025, which was primarily because the gross profit margin of the Company's pharmacy wholesale customers newly acquired in the six months ended June 30, 2024 was higher than that of customers in the six months ended June 30, 2025.
      • Sales and marketing expenses increased by 11.6% from RMB24.9 million in the six months ended June 30, 2024 to RMB27.8 million (US$3.9 million) in the six months ended June 30, 2025, primarily due to higher service fees to doctors and increased staff costs in line with the growth in revenues from Internet hospital business, partially offset by a slight decrease in advertising and promotion costs resulting from a relatively stable pharmaceutical supply chain business.
      • General and administrative expenses increased by 53.5% from RMB6.8 million in the six months ended June 30, 2024 to RMB10.5 million (US$1.5 million) in the six months ended June 30, 2025, primarily due to the increase in consultancy and professional service fees incurred in connection with the Company's initial public offering, partially offset by the decrease in expected credit loss recognized resulting from the efforts for collection of receivables.
      • Research and development expense remained relatively stable at RMB1.5 million (US$0.2 million) for the six months ended June 30, 2024 and 2025.
      • Impairment loss on long-lived assets recorded was RMB0.02 million and RMB2.0 million (US$0.3 million) for the six months ended June 30, 2024 and 2025, respectively.
      • Loss from operation was RMB13.5 million (US$1.9 million) for the six months ended June 30, 2025, compared with RMB8.9 million for the six months ended June 30, 2024.
      • Net loss was RMB19.9 million (US$2.8 million) for the six months ended June 30, 2025, compared with RMB RMB14.0 million for the six months ended June 30, 2024.
      • Net loss per share, basic and diluted, was RMB11.45 (US$1.60) for the six months ended June 30, 2025, compared with RMB10.58 for the six months ended June 30, 2024.

      Financial Condition

      • Cash and cash equivalents of RMB5.7 million (US$0.8 million) as of June 30, 2025, compared to RMB7.7 million as of December 31, 2024.
      • Net cash used in operating activities was RMB15.0 million (US$2.1 million) for the six months ended June 30, 2025, compared with RMB10.6 million for the six months ended June 30, 2024.
      • Net cash used in investing activities was RMB512,200 (US$71,500) for the six months ended June 30, 2025, compared with RMB17,862 for the six months ended June 30, 2024.
      • Net cash provided by financing activities was RMB13.6 million (US$1.9 million) for the six months ended June 30, 2025, compared with RMB16.6 million for the six months ended June 30, 2024.

      Exchange Rate Information

      This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.1636 to US$1.00, the rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board on June 30, 2025.

      Recent Development

      On October 9, 2025, the Company completed its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. On October 10, 2025, the underwriter of the Offering fully exercised its over-allotment option to purchase an additional 750,000 American Depositary Shares of the Company at the public offering price of US$4.00 per share. The gross proceeds were US$23,000,016 from the Offering, before deducting underwriting discounts and commissions, and other expenses. The Company's ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker symbol "POM."

      About POMDOCTOR LIMITED

      POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.

      Forward-Looking Statements

      Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.

      For more information, please contact:

      POMDOCTOR LIMITED
      Investor Relations Department
      Email: [email protected]

      Ascent Investor Relations LLC
      Tina Xiao
      Phone: +1-646-932-7242
      Email: [email protected]

      POMDOCTOR LIMITED

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS






      December 31,
      2024



      June 30,
      2025



      June 30,
      2025




      RMB



      RMB



      US$


      Assets










      Current assets:










      Cash and cash equivalents (including amounts of the consolidated VIEs of
         RMB7,596,708 and RMB5,579,802 (US$778,910) as of December 31,
         2024 and June 30, 2025, respectively)



      7,651,695




      5,746,989




      802,249


      Accounts receivable, net (including amounts of the consolidated VIEs of
         RMB8,374,608 and RMB6,128,066 (US$855,445) as of December 31,
         2024 and June 30, 2025, respectively)



      8,374,608




      6,128,066




      855,445


      Accounts receivable – a related party (including amounts of the
         consolidated VIEs of RMB424,259 and RMB584,802 (US$81,635) as
         of December 31, 2024 and June 30, 2025, respectively)



      424,259




      584,802




      81,635


      Amount due from related parties (including amounts of the consolidated
         VIEs of RMB6,070,945 and RMB9,643,039 (US$1,346,117) as of
         December 31, 2024 and June 30, 2025, respectively)



      5,632,987




      7,418,671




      1,035,607


      Inventories (including amounts of the consolidated VIEs of
         RMB9,165,973 and RMB6,447,637 (US$900,055) as of December 31,
         2024 and June 30, 2025, respectively)



      9,165,973




      6,447,637




      900,055


      Other receivables, net (including amounts of the consolidated VIEs of
         RMB5,318,724 and RMB5,231,722 (US$730,319) as of December 31,
         2024 and June 30, 2025, respectively)



      5,318,724




      5,231,722




      730,319


      Advances to suppliers (including amounts of the consolidated VIEs of
         RMB929,167 and RMB2,921,966 (US$407,891) as of December 31,
         2024 and June 30, 2025, respectively)



      929,167




      2,921,966




      407,891


      Total current assets



      37,497,413




      34,479,853




      4,813,201


      Non-current assets:













      Property and equipment, net (including amounts of the consolidated VIEs
         of RMB461,362 and RMB394,107 (US$55,015) as of December 31,
         2024 and June 30, 2025, respectively)



      461,362




      394,107




      55,015


      Other non-current assets (including amounts of the consolidated VIEs of
         RMB831,132 and RMB1,307,832 (US$182,566) as of December 31,
         2024 and June 30, 2025, respectively)



      831,132




      1,307,832




      182,566


      Deferred offering costs (including amounts of the consolidated VIEs of
         RMB7,437,679 and RMB6,007,339 (US$838,592) as of December 31,
         2024 and June 30, 2025, respectively)



      7,437,679




      7,690,157




      1,073,505


      Total non-current assets



      8,730,173




      9,392,096




      1,311,086


      Total assets



      46,227,586




      43,871,949




      6,124,287




      POMDOCTOR LIMITED

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued)






      December 31,
      2024



      June 30,
      2025



      June 30,
      2025




      RMB



      RMB



      US$


      Liabilities










      Current liabilities:










      Accounts payable (including amounts of the consolidated VIEs of
         RMB25,320,486 and RMB25,164,804 (US$3,512,871) as of December
         31, 2024 and June 30, 2025, respectively)



      25,320,486




      25,164,804




      3,512,871


      Accounts payable – a related party (including amounts of the consolidated
         VIEs of RMB25,891 and RMB13,711 (US$1,914) as of December 31,
         2024 and June 30, 2025, respectively)



      25,891




      13,711




      1,914


      Short-term bank loans (including amounts of the consolidated VIEs of
         RMB34,958,333 and RMB34,708,333 (US$4,845,096) as of December
         31, 2024 and June 30, 2025, respectively)



      34,958,333




      34,708,333




      4,845,096


      Long-term bank loans, current (including amounts of the consolidated
         VIEs of RMB300,000 and RMB2,400,000 (US$335,027) as of
         December 31, 2024 and June 30, 2025, respectively)



      300,000




      2,400,000




      335,027


      Long-term loans, current (including amounts of the consolidated VIEs of
         RMB10,000,000 and RMB10,000,000 (US$1,395,946) as of December
         31, 2024 and June 30, 2025, respectively)



      10,000,000




      10,000,000




      1,395,946


      Long-term loans from third parties, current (including amounts of the
         consolidated VIEs of RMB2,320,082 and RMB2,295,082
         (US$320,381) as of December 31, 2024 and June 30, 2025,
         respectively)



      2,320,082




      2,295,082




      320,381


      Salary and welfare payable (including amounts of the consolidated VIEs   
         of RMB15,375,537 and RMB15,543,259 (US$2,169,755) as of
         December 31, 2024 and June 30, 2025, respectively)



      15,375,537




      15,543,259




      2,169,755


      Advance from customers (including amounts of the consolidated VIEs of
         RMB1,756,046 and RMB942,724 (US$131,599) as of December 31,
         2024 and June 30, 2025, respectively)



      1,756,046




      942,724




      131,599


      Value added tax ("VAT") and other tax payable (including amounts of the
         consolidated VIEs of RMB815,462 and RMB998,295 (US$139,357) as
         of December 31, 2024 and June 30, 2025, respectively)



      815,462




      998,295




      139,357


      Other payables (including amounts of the consolidated VIEs of
         RMB12,888,550 and RMB10,543,238 (US$1,471,777) as of December
         31, 2024 and June 30, 2025, respectively)



      12,888,750




      10,543,438




      1,471,806


      Accrued liabilities (including amounts of the consolidated VIEs of
         RMB9,712,966 and RMB11,564,144 (US$1,614,292) as of December
         31, 2024 and June 30, 2025, respectively)



      9,712,966




      11,564,144




      1,614,292


      Short-term loans from third parties (including amounts of the consolidated
         VIEs of RMB11,551,614 and RMB7,194,342 (US$1,004,291) as of
         December 31, 2024 and June 30, 2025, respectively)



      11,551,614




      7,194,342




      1,004,291


      Loans from related parties, current (including amounts of the consolidated
         VIEs of RMB13,821,875 and RMB33,194,670 (US$4,633,797) as of
         December 31, 2024 and June 30, 2025, respectively)



      13,821,875




      33,194,670




      4,633,797


      Amount due to related parties (including amounts of the consolidated
         VIEs of RMB36,829,010 and RMB42,403,073 (US$5,919,241) as of
         December 31, 2024 and June 30, 2025, respectively)



      36,829,010




      42,403,073




      5,919,241




      POMDOCTOR LIMITED

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued)






      December 31,
      2024



      June 30,
      2025



      June 30,
      2025




      RMB



      RMB



      US$


      Operating lease liabilities, current (including amounts of the
         consolidated VIEs of RMB1,388,863 and RMB1,790,319
         (US$249,919) as of December 31, 2024 and June 30, 2025,
         respectively)



      1,388,863




      1,790,319




      249,919


      Other current liabilities (including amounts of the consolidated
         VIEs of RMB2,080,556 and RMB237,580 (US$33,165) as of  
         December 31, 2024 and June 30, 2025, respectively)



      2,080,556




      237,580




      33,165


      Total current liabilities



      179,145,471




      198,993,774




      27,778,457















      Long-term bank loans, noncurrent (including amounts of the
         consolidated VIEs of RMB8,400,000 and RMB5,700,000
         (US$795,689) as of December 31, 2024 and June 30, 2025,
         respectively)



      8,400,000




      5,700,000




      795,689


      Loans from related parties, noncurrent (including amounts of the
         consolidated VIEs of RMB356,690,859 and RMB356,390,859
         (US$49,750,246) as of December 31, 2024 and June 30, 2025,
         respectively)



      356,690,859




      356,390,859




      49,750,246


      Operating lease liabilities, noncurrent (including amounts of the
         consolidated VIEs of RMB1,672,218 and RMB2,346,664
         (US$327,582) as of December 31, 2024 and June 30, 2025,
         respectively)



      1,672,218




      2,346,664




      327,582


      Total non-current liabilities



      366,763,077




      364,437,523




      50,873,517


      Total liabilities



      545,908,548




      563,431,297




      78,651,974















      Commitments and contingencies



      —




      —




      —















      Mezzanine equity













      Convertible redeemable preferred shares (US$0.0001 par value;
         12,597,228 shares authorized, issued and outstanding as of
         December 31, 2024 and June 30, 2025)



      1,595,051,558




      1,642,498,390




      229,283,934


      Redeemable non-controlling interests



      168,671,234




      173,630,137




      24,237,833


      Total mezzanine equity



      1,763,722,792




      1,816,128,527




      253,521,767















      Equity (deficit)













      Class A ordinary shares (US$0.0001 par value; 485,360,730
         shares authorized, 4,268,156 shares issued and outstanding as of
         December 31, 2024 and June 30, 2025)



      2,988




      2,988




      417


      Class B Ordinary shares (US$0.0001 par value; 2,042,042 shares
         authorized and outstanding as of December 31, 2024 and
         June 30, 2025, respectively)



      1,408




      1,408




      197


      Subscription receivable



      (1,608)




      (1,608)




      (224)


      Accumulated deficit



      (2,263,419,477)




      (2,335,709,744)




      (326,052,508)


      Accumulated other comprehensive (loss) income



      (5,231)




      1,875




      262


      Total Pomdoctor Limited's shareholders' deficit



      (2,263,421,920)




      (2,335,705,081)




      (326,051,856)


      Noncontrolling interests



      18,166




      17,206




      2,402


      Total deficit



      (2,263,403,754)




      (2,335,687,875)




      (326,049,454)


      Total liabilities, mezzanine equity and deficit



      46,227,586




      43,871,949




      6,124,287


      POMDOCTOR LIMITED

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND

      COMPREHENSIVE LOSS






      For Six Months Ended June 30,




      2024



      2025



      2025




      RMB



      RMB



      US$


      Net revenues – third parties



      149,266,587




      174,283,295




      24,329,010


      Net revenues – a related party



      897,822




      186,556




      26,042


      Net revenues



      150,164,409




      174,469,851




      24,355,052


      Cost of revenues



      125,823,734




      146,152,450




      20,402,095


      Gross profit



      24,340,675




      28,317,401




      3,952,957















      Operating expenses:













      Sales and marketing expenses



      24,884,898




      27,761,736




      3,875,389


      General and administrative expenses



      6,835,897




      10,494,487




      1,464,974


      Research and development expenses



      1,507,847




      1,479,909




      206,587


      Impairment loss on long-lived assets



      17,861




      2,041,299




      284,954


      Total operating expenses



      33,246,503




      41,777,431




      5,831,904


      Loss from operations



      (8,905,828)




      (13,460,030)




      (1,878,947)















      Other income (expenses):













      Other income



      1,078,270




      28,027




      3,912


      Other expense



      (33,681)




      (130,291)




      (18,188)


      Interest expense



      (6,179,172)




      (6,471,198)




      (903,344)


      Government grants



      13,858




      148,000




      20,660


      Total other expense, net



      (5,120,725)




      (6,425,462)




      (896,960)


      Loss before income tax



      (14,026,553)




      (19,885,492)




      (2,775,907)


      Income tax expense



      —




      —




      —


      Net loss



      (14,026,553)




      (19,885,492)




      (2,775,907)


      Accretion to redemption value of mezzanine equity



      (52,695,272)




      (52,405,735)




      (7,315,559)


      Less: Net income (loss) attributable to noncontrolling interests



      27,639




      (960)




      (134)


      Net loss attributable to the Pomdoctor Limited's ordinary
         shareholders



      (66,749,464)




      (72,290,267)




      (10,091,332)


      Net loss



      (14,026,553)




      (19,885,492)




      (2,775,907)


      Other comprehensive (loss) income:













      Total other comprehensive (loss) income



      (3,970)




      7,106




      992


      Total comprehensive loss



      (14,030,523)




      (19,878,386)




      (2,774,915)


      Accretion to redemption value of mezzanine equity



      (52,695,272)




      (52,405,735)




      (7,315,559)


      Less: comprehensive income (loss) attributable to noncontrolling
         interests



      27,639




      (960)




      (134)


      Comprehensive loss attributable to the Pomdoctor Limited's
         ordinary shareholders



      (66,753,434)




      (72,283,161)




      (10,090,340)















      Loss per share













            Basic and diluted



      (10.58)




      (11.45)




      (1.60)















      Weighted average number of ordinary shares outstanding*













            Basic and diluted



      6,310,198




      6,310,198




      6,310,198




      *  Ordinary shares and share data have been retroactively restated to give effect to the nominal share issuance for
          the Reorganization completed on August 8, 2024


      POMDOCTOR LIMITED

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS






      For Six Months Ended June 30,




      2024



      2025



      2025




      RMB



      RMB



      US$


      Net cash used in operating activities 



      (10,631,121)




      (14,987,658)




      (2,092,195)


      Cash flows from investing activities:




      Payment for purchase of property and equipment



      (17,862)




      (2,200)




      (307)


      Payment for long-term investment



      —




      (510,000)




      (71,193)


      Net cash used in investing activities



      (17,862)




      (512,200)




      (71,500)















      Cash flows from financing activities:













      Loans from related parties



      11,219,986




      24,750,310




      3,455,010


      Repayment to related parties



      (14,436,941)




      (5,677,514)




      (792,550)


      Proceeds from short-term bank loans



      37,000,000




      29,000,000




      4,048,244


      Repayment of short-term bank loans



      (19,300,000)




      (29,250,000)




      (4,083,143)


      Repayment of long-term bank loans



      (54,628)




      (600,000)




      (83,757)


      Loans from third parties



      8,759,366




      1,600,000




      223,351


      Repayment to third parties



      (4,968,912)




      (5,982,272)




      (835,093)


      Payment for deferred offering cost



      (1,656,745)




      (252,478)




      (35,245)


      Net cash provided by financing activities



      16,562,126




      13,588,046




      1,896,817


      Effect of exchange rate changes



      (3,970)




      7,106




      992


      Net increase (decrease) in cash and cash equivalents and restricted
      cash



      5,909,173




      (1,904,706)




      (265,886)


      Cash and cash equivalents and restricted cash at beginning of the
         period



      6,805,099




      7,651,695




      1,068,135




      POMDOCTOR LIMITED

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)






      For Six Months Ended June 30,




      2024



      2025



      2025




      RMB



      RMB



      US$


         Including:










            Cash and cash equivalents at beginning of the period



      6,717,031




      7,651,695




      1,068,135


            Restricted cash at beginning of the period



      88,068




      —




      —















      Cash and cash equivalents and restricted cash at end of the period



      12,714,272




      5,746,989




      802,249















      Including:













            Cash and cash equivalents at end of the period



      12,714,272




      5,746,989




      802,249















      Supplemental disclosures of cash flows information:













      Cash paid for interest expense



      1,130,609




      2,382,125




      332,532















      Supplemental disclosure of noncash investing and financing activities:













      Operating lease right-of-use assets obtained in exchange for new operating
          lease liabilities



      —




      2,039,099




      284,647


      SOURCE POMDOCTOR LIMITED

      Modal title

      Also from this source

      POMDOCTOR LIMITED Highlights Real-World Data as a Strategic Foundation for AI-Enabled Healthcare Solutions

      POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence...

      POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement

      POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and ...

      More Releases From This Source

      Explore

      Internet Technology

      Internet Technology

      Telecommunications Industry

      Telecommunications Industry

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.